Background: Therapy for acute myeloid leukemia (AML) has largely remained unchanged, and outcomes are unsatisfactory. We sought to analyze outcomes of AML patients enrolled in phase I studies to determine whether overall response rates (ORR) and mortality rates have changed over time.
Over the past four decades, the therapeutic advancements in the management of acute myeloid leukemia (AML) have been minimal. "7+3," defined as seven days of continuous infusion cytarabine (100-200 mg/m 2 /day) and three days of an anthracycline (most commonly daunorubicin 45-90 mg/m 2 /day), was originally studied in the 1970s by Cancer and Leukemia Group B (CALGB) cooperative group studies and remains the standard induction regimen for all patients younger than 65 to 70 years who can withstand intensive therapy (1) (2) (3) (4) . For younger AML patients (≤55 years), the complete remission (CR) rate and median overall survival (OS) are approximately 63.9% and 18.8 months, respectively, whereas outcomes are considerably worse in older AML patients (>55 years: CR rates <46.0% and median OS <9 months) (5) . A recent European retrospective analysis reviewed overall outcomes in greater than 48 000 AML patients (≥age 15 years) between 1997 and 2008. A marginal improvement was seen in article five-year OS, from 12.6% in 1997 to 1999 to 14.8% in 2006 to 2008, with no improvement in OS in those age 65 years and older (6) .
Excluding all-trans retinoic acid (ATRA) and arsenic trioxide for acute promyelocytic leukemia (APL), no new agents have been approved and incorporated into standard of care for AML since idarubicin was approved in combination (ie, 7+3) in 1990. Induction regimens consisting of idarubicin vs daunorubicin have yielded similar outcomes (7) . Gemtuzumab ozogamicin (GO), a monoclonal antibody targeting CD33 antigen linked with calicheamicin, received accelerated approval by the United States Federal Drug Administration (FDA) in 2000 after GO showed efficacy as a single agent in relapsed and refractory AML (8, 9) . However, GO was withdrawn from the United States market by Pfizer in 2010 after a confirmatory phase III trial revealed toxicity and efficacy concerns (10) . A plethora of other new agents with distinct biologic activity have been studied in AML without successful incorporation into standard clinical practice. In 2015, greater than 18 000 patients are expected to be diagnosed with AML, with close to 11 000 deaths in the United States alone, and the incidence of AML is increasing (11, 12) . New therapies are urgently needed to improve treatment outcomes for these patients.
We retrospectively analyzed outcomes of patients with AML enrolled in National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored phase I clinical trials using the NCI Phase I Clinical Trials Database. Our hypothesis was that outcomes of AML patients enrolled in phase I studies are improving over time as newer and presumably more effective agents are developed.
Methods

Study Design
A retrospective analysis was performed on NCI/CTEP-sponsored phase I clinical studies from 1986 to 2009. The database is maintained by Theradex, an international contract research organization, and is kept up to date by the investigators performing clinical trials and the CTEP of the NCI.
Participants
Sixty-five phase I studies were identified in leukemia, and 45 of these studies principally enrolled AML patients between 1986 to 2009 (Consort Diagram, Figure 1 ). Adults age 18 years and older with pathologic confirmation of AML were included in the analysis. Clinical and biologic features were analyzed prior to and after enrollment on study. All studies were conducted in accordance with the Declaration of Helsinki and were approved by the ethics committees of each of the participating centers. Informed consent was obtained from each participant for each of the studies reported.
Statistical Analysis
The primary objectives of this analysis were to estimate overall response rates (ORR: CR +partial remission) and all-cause early mortality, defined as death within 30 or 60 days of initiation of therapy, for the whole study and within specific subgroups of patients. CR with incomplete blood count recovery (CRi) was utilized as an ORR criterion after it was incorporated into the International Working Group Response Criteria for AML in 2003 (13) . Differences in the rates of mortality and ORR over time were explored by categorizing time into five subgroups roughly divided into five-year increments: 1986 to 1990, 1991 to 1995, 1996 to 2000, 2001 to 2005, and 2006 to 2009. Changes in ORR and mortality rates across these year groups were estimated with multivariable logistic regression models adjusting for patient age, number of prior therapies, and white blood cell count (WBC) at the start of therapy. The overall effect of year group was tested using a Wald test of nested regression models. To determine if the differences in ORR and mortality by year groups was modified by patient age, number of prior therapies, or single-agent vs combination therapy, the corresponding interactions terms were included in the models and retained in the final model if statistically significant (P < .05). The average change in the yearly number of patients enrolled was estimated with a simple linear regression model. Differences in patient characteristics were described by Fisher's exact test with a two-sided P value. 
Results
Patient Characteristics
Treatment Outcomes: Response Rates
Forty-two out of 711 (5.9%) patients did not have a response assessment documented and were thus excluded from the ORR analysis ( Figure 1 ). The ORR for the remaining cohort of 669 patients was 15.4% (single agent: 4.7% vs combination: 22.8%; odds ratio = 5.95, 95% CI = 3.22 to 11.9, P < .001). Downloaded from https://academic.oup.com/jnci/article-abstract/108/3/djv335/2412398 by guest on 28 January 2019 article to 2009 compared with earlier years (P < .001), the difference seems to be largely driven by increased use of combination therapies. When comparing the overall effect of year groups on the probability of response (Supplementary Table 1 , available online), there was a statistically significant improvement of ORRs over time in patients younger than age 60 years (P = .01) and a nonsignificant trend of improved ORRs in patients age 60 years and older (P = .10). Notably, the ORR for those younger than age 60 years and age 60 years and older in 2006 to 2009 was 26.4% and 20.4%, respectively. A test for interaction did not reveal any statistical differences in ORRs between age and year group (P = .58). Comparison of ORRs stratified by number of prior therapies (0 vs 1-2 vs ≥3) revealed no differences in ORR among those receiving zero or one to two prior therapies but statistically significant improvement over time in patients with three or more prior therapies (P = .001). Finally, there was also a statistically significant improvement in ORR over time in patients treated on combination studies (P = .03) but not on single-agent trials (P = .43). Test for interaction did not reveal any statistical differences in ORRs between type of study (ie, single agent vs combination) and year group (P = .51).
Treatment Outcomes: Early Mortality
All-cause early mortality was subdivided into 30-day and 60-day mortality rates. The 30-day and 60-day mortality rates for the entire cohort were 11.1% (single agent: 13.8% vs combination: 9.2%) and 22.6% (single agent: 28.0% vs combination: 19.0%), respectively. Thirty-day mortality did not statistically significantly change over time (1986 to 1990: 11.5% vs 2006 to 2009: 8.6%), whereas 60-day mortality rates were statistically significantly higher in earlier years compared with 2006 to 2009 (P = .009). Given the apparent improvement in 60-day mortality rates (when compared with 30-day mortality), we analyzed 60-day mortality rates as a function of age, number of prior therapies, and type of clinical study. Figure 4 depicts the 60-day mortality rates among each subgroup for (A) the whole cohort and stratified by (B) age, (C) article number of prior therapies, and (D) type of study (ie, single agent vs combination). Table 2 provides estimates of odds ratios for year subgroup and 60-day mortality rates. There was a statistically significant improvement in 60-day mortality rates over time (P = .009). When comparing 60-day mortality rates for patient subgroups by year group (Supplementary Table 1 , available online), there was a statistically significant improvement in 60-day mortality rates in patients younger than age 60 years (P = .004) but not in patients age 60 years and older (P = .20). However, a test for interaction did not reveal any statistical differences in 60-day mortality rates between age and year group (P = .31). Similar to ORRs, 60-day mortality rates statistically significantly improved in heavily pretreated patients (ie, ≥3 prior therapies, P < .001) but not in patients with zero or one to two prior therapies. Finally, there was an improvement of 60-day mortality rates in the 2006 to 2009 subgroup compared with earlier years in patients treated on combination studies (P = .08). A test for interaction showed no significant differences between year groups and type of study on the probability of 60-day mortality (P = .76).
Discussion
The persistently poor outcome of AML patients underscores the need for the development and implementation of novel agents. This retrospective analysis of CTEP-sponsored phase I clinical trials demonstrates an increase in the overall enrollment of AML patients on phase I clinical trials over the last 23 years. The concomitant increase in combination studies and inclusion of patients with newly diagnosed AML has been accompanied by an improvement in ORRs and all-cause early mortality rates, with a promising ORR of 22.6% from 2006 to 2009. ORRs were shown to be improving particularly in younger patients (ie, <60 years) and heavily pretreated patients. Although causes of death were not identified in this analysis, early mortality improvements may be partly because of the advances in supportive care and antimicrobial use, rather than a superior safety profile of novel antileukemic agents.
The American Society of Clinical Oncology (ASCO) Policy Statement Update by Weber et al. (14) recently commented on the critical importance of phase I clinical trials in cancer. The primary objective of phase I clinical trials is to define the safety and tolerability of a new drug or treatment regimen and to describe the dose-limiting toxicities observed during dose determination. The majority of phase I clinical trials also evaluate efficacy as a secondary endpoint. Once a tolerable dose and schedule are defined, clinical studies evaluating new oncology agents proceed only if preliminary antitumor activity is demonstrated. Thus, evaluation of response rate as a * Odds ratios (95% confidence intervals) from multivariable logistic regression models for the association between categories of time (year on study) and overall response rate adjusted for age (continuous), number of prior therapies, and white blood cell count. Year was grouped and compared with the reference group of studies in 2006-2009. CI = confidence interval; OR = odds ratio. † P values for Wald tests from nested models for the overall effect of year groups on the probability of response or 60-day mortality. Over the last five years, there have been 23 new therapeutic agents approved by the FDA for hematologic malignancies (chronic myeloid leukemia, n = 5; chronic lymphocytic leukemia, n = 5; lymphomas, n = 5; acute lymphoblastic leukemia, n = 4; multiple myeloma, n = 3; myelofibrosis/polycythemia vera, n = 1). In contrast, no new agents have been approved by the FDA for non-APL AML since 1990, with the exception of GO, which received accelerated approval in 2000 but was withdrawn from the market in 2010 because of safety and efficacy concerns. Limitations in AML drug development include: 1) lack of consistent and standard treatment approaches in AML, which confounds the analyses of OS and disease-free survival endpoints, 2) inherent molecular and clinical heterogeneity of patients with AML, 3) variability in the monitoring and treatment of minimal residual disease, and 4) initial evaluation of new agents restricted to patients with chemoresistant/refractory disease, posing heightened challenges for establishing markers of efficacy in an extremely poor-risk patient population (19, 20) . Designing and implementing clinical trials in specific subpopulations of AML patients with concomitant pharmacodynamic studies to identify biomarkers of drug sensitivity and response may help to circumvent some of these shortcomings.
Given the underlying complexity in AML pathogenesis and the inherent heterogeneity of the AML population as a whole, sustained single-agent activity is unlikely. Therefore, the investigation of new agents in combination with mechanistically complementary agents should be evaluated early in the drug development process. Precision-targeted approaches to identify patients for specific therapeutic interventions and immunotherapeutic strategies show tremendous promise in cancer. Such approaches should be evaluated early to identify effective combinatorial approaches and to accelerate drug approval in AML. Newly diagnosed poor-risk AML patients, particularly in the elderly population, should be included in early-phase clinical trials to increase the probability of identifying antileukemic activity in a non-heavily pretreated subgroup.
There are currently six active CTEP-sponsored clinical studies in AML patients (Table 3 ). An additional six phase I and three phase II trials in AML have completed accrual within the past two years. The active studies have a total planned enrollment of 412 patients. Four studies involve complementary combinatorial agents in newly diagnosed untreated patients, while two phase Ib studies examine single-agent ipilimumab in AML patients in CR and relapsed hematologic malignancies post allogeneic stem cell transplantation, respectively. This is the first comprehensive study to analyze and evaluate outcomes of patients with AML treated on phase I studies, to our knowledge. This analysis was limited to phase I studies in order to comprehensively assess whether outcomes are being improved early in the drug development process. This provides a vantage point to evaluate whether the appropriate patient populations and disease settings are being addressed early in the investigation of novel agents and the changes over time. Nonetheless, our evaluation of AML patients in early-phase clinical trials has limitations that may affect the generalizability of these observations. Given that this analysis focused only on phase I clinical studies, it would be important to compare these results to later-phase clinical trials (ie, phase II and III) to determine whether the same trends and changes are occurring over time. Moreover, these findings relate exclusively to NCI/CTEP-sponsored phase I trials; these results may be disparate when analyzing industrysponsored or cooperative group studies in AML. Additionally, a limited number of clinical variables were available for our analysis. We did not have access to cytogenetic or molecular abnormalities, types of prior therapies, performance status, or disease-free survival. Secondary AML (treatment related AML or AML preexisting from an antecedent hematologic disorder), a subtype of AML with an extremely poor prognosis, was not predefined in our database. It is likely that secondary AML comprised a substantial proportion of the patient population enrolled in these studies, particularly in the most recent cohorts, as newly diagnosed poor-risk AML patients were increasingly included in the eligibility of phase I studies. Comparing outcomes for de novo AML vs secondary AML would be important in the evaluation of any differences in ORRs and mortality rates on phase I clinical trials in these subsets of patients. Despite these limitations, our findings encompass results from 711 patients enrolled in 45 phase I studies over a 23-year time period. These findings, at least in part, reflect the general trends seen in AML accrual in the United States and clinical outcomes on AML phase I studies over time.
In conclusion, our findings reveal that there has been a statistically significant increase in the enrollment of AML patients on phase I clinical trials over the last 23 years, with improvement in both ORRs and 60-day mortality rates over time. The increasing study of combinations of novel agents, either with established antileukemic cytotoxic drugs or with other investigational agents, in early-phase AML clinical trials has led to an ORR of 22.6% in 2006 to 2009. Early-phase clinical trials should not be the last resort for AML patients. Unfortunately, only 5% to 10% of adult AML patients enroll in clinical trials, and even fewer enroll in phase I studies (21) . Educating patients and clinicians about the benefits of earlyphase clinical trials is necessary for successful drug development in AML. 
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